title: 2014 Update of the drug resistance mutations in HIV-1.
abstract: This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
authors.affiliation: University of Medical Center Utrecht, The Netherlands.
authors.forename: Annemarie M
authors.initials: AM
authors.lastname: Wensing
authors.affiliation: Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.affiliation: University Hospital Zurich, University of Zurich, Switzerland.
authors.forename: Huldrych F
authors.initials: HF
authors.lastname: Günthard
authors.affiliation: Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
authors.forename: Victoria A
authors.initials: VA
authors.lastname: Johnson
authors.affiliation: HIV Unit and IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors.forename: Roger
authors.initials: R
authors.lastname: Paredes
authors.affiliation: University of College London, United Kingdom, and Africa Centre for Health and Population Studies, University of KwaZulu Natal, Mtubatuba, South Africa.
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.affiliation: Stanford University Medical School, Stanford, CA, USA.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Shafer
authors.affiliation: Veterans Affairs San Diego Healthcare System and University of California San Diego, La Jolla, CA, USA.
authors.forename: Douglas D
authors.initials: DD
authors.lastname: Richman
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D020125:Mutation, Missense; D017354:Point Mutation
chemical_list: D019380:Anti-HIV Agents
references.citation: J Clin Invest. 2013 Sep;123(9):3848-60
references.pmid: 23979165
references.citation: Retrovirology. 2012 Aug 06;9:63
references.pmid: 22867298
references.citation: Antivir Ther. 2014;19(8):819-23
references.pmid: 24704709
references.citation: J Antimicrob Chemother. 2014 Aug;69(8):2118-22
references.pmid: 24710029
references.citation: Antiviral Res. 2012 Jul;95(1):9-11
references.pmid: 22564967
references.citation: J Antimicrob Chemother. 2013 Oct;68(10):2199-204
references.pmid: 23749955
references.citation: JAMA. 2014 Jul 23-30;312(4):410-25
references.pmid: 25038359
references.citation: Top Antivir Med. 2013 Feb-Mar;21(1):6-14
references.pmid: 23596273
references.citation: Clin Infect Dis. 2008 Jul 15;47(2):266-85
references.pmid: 18549313